Pharmacy benefits and the use of drugs by the chronically ill

JAMA

Volumn 291, Issue 19, 2004, Pages 2344-2350

  Goldman, Dana P ^a,b   Joyce, Geoffrey F ^a   Escarce, Jose J ^a   Pace, Jennifer E ^a   Solomon, Matthew D ^a   Laouri, Marianne ^c,d   Landsman, Pamela B ^b   Teutsch, Steven M ^b  

^a RAND CORPORATION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c California HealthCare Foundation   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CHRONIC DISEASE; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; COST; DRUG SELF ADMINISTRATION; ECONOMICS; HEALTH INSURANCE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTION; REGRESSION ANALYSIS; STATISTICS; UTILIZATION REVIEW;

ADULT; CHRONIC DISEASE; COST SHARING; DRUG COSTS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SELF ADMINISTRATION; UNITED STATES;

EID: 2442611765     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.19.2344     Document Type: Article

References (15)

1. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733-1739.
2. Lurie N, Ward NB, Shapiro MF, Gallego C, Vaghaiwalla R, Brook RH. Termination of Medi-Cal benefits: a follow-up study one year later. N Engl J Med. 1986;314:1266-1268.
3. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
4. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO patients. Health Serv Res. 1997;32:103-122.
5. Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry. 1985;22:396-403.
6. Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA. 2001;286:1732-1739.
7. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
8. Lohr KN, Brook RH, Kamberg CJ, et al. Use of selected drugs and procedures. Med Care. 1986;24(9 suppl):S39-S50.
9. Harris BL, Stergachis A, Reid LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28:907-917.
10. 2000 Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 2000.
11. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570-1576.
12. Knowler WC, Barrett-Connor E, Fowler SE, et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
13. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Sourmerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346:822-829.
14. Motheral BR, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293-1304.
15. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered copayments on the use of preferred brand medications. Med Care. 2003;41:398-406.